Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20263246 | 1.00 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263160 | 1.00 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL30280478 | 1.00 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL30280460 | 1.00 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263171 | 0.91 | CFTR (0.84) | CFTRPIK3CD | |
| SCHEMBL30280506 | 0.91 | CFTR (0.84) | CFTRPIK3CD | |
| SCHEMBL20263183 | 0.90 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263192 | 0.87 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL30280600 | 0.87 | CFTR (1.00) | CFTRPIK3CD | |
| SCHEMBL20263190 | 0.87 | CFTR (1.00) | CFTRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110300589-B | Bicyclic heteroaryl derivatives as CFTR potentiators | 囊性纤维化基金会 | 2023-03-10 | — | — | CN | claimed |
| EP-3554506-B1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2021-04-28 | — | — | EP | claimed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | claimed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | claimed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | CFTR 1/4885PIK3CD 589/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | CFTR 1/4885PIK3CD 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.